Scope and Claims Analysis of US Patent 8,686,026: Amorphous Solid Dispersion and Hydrophilic Polymer + Surfactant Formulations for Dimethyl (2S,2′S)–1,1′-… Dicarbamate
Executive summary: US Patent 8,686,026 claims a solid amorphous composition of a specific stereochemically defined dimethyl dicarbamate (described in the claims) formulated with a hydrophilic polymer and a pharmaceutically acceptable surfactant. The core novelty is the amorphous solid dispersion / amorphous solid dispersion architecture, constrained by polymer thermal property (Tg ≥ 50°C) and surfactant emulsifier power (HLB ≥ 10), with dependent claim coverage for copovidone and specific surfactants including TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) and sorbitan mono laurate. Claim set also extends to combination products by adding anti-HCV agents and HCV protease/polymerase inhibitors, plus examples of HCV direct-acting antivirals (DAAs).
What is US Patent 8,686,026 claiming at the highest level?
Direct answer: US 8,686,026 claims a solid amorphous drug composition containing a defined dimethyl dicarbamate active, plus (i) a hydrophilic polymer and (ii) a pharmaceutically acceptable surfactant, with further claim scope for amorphous solid dispersions and specific polymer/surfactant selection criteria.
Claim 1: independent claim scope (core formulation)
Claim 1 is structured as a three-component, amorphous solid composition:
-
Active ingredient (very narrow by structure and stereochemistry)
Dimethyl (2S,2′S)-1,1′-((2S,2′S)-2,2′-(4,4′-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate, or a pharmaceutically acceptable salt.
-
Amorphous requirement (materials constraint)
The active must be in an amorphous form.
-
Excipients required (materials + functional constraints)
- a hydrophilic polymer
- a pharmaceutically acceptable surfactant
Legal/strategic read: Claim 1 ties infringement to: (i) using this specific active (or a salt), (ii) ensuring amorphous solid state, and (iii) using both a hydrophilic polymer and a surfactant in the solid composition.
How broad is the protection: amorphous solid composition vs “solid dispersion”?
Direct answer: The patent protects amorphous compositions generally (Claim 1), and it provides additional layered scope for solid dispersions and for amorphous solid dispersions (Claims 2 and 6), plus narrower polymer/surfactant selection rules.
Claim 2: solid dispersion architecture
Claim 2 narrows Claim 1 by requiring the amorphous solid composition be a solid dispersion including the active, polymer, and surfactant.
Why it matters: This creates two infringement pathways in practice:
- Products meeting Claim 1 without being a “solid dispersion” could still fall under Claim 1 (if “amorphous form” and excipient requirements are met).
- Products specifically engineered as solid dispersions are more directly captured by Claim 2 and its dependents.
Claim 6: amorphous solid dispersion (stacking constraint)
Claim 6 requires an amorphous solid dispersion which further comprises the surfactant.
This effectively tightens “solid dispersion” into “amorphous solid dispersion,” reducing design-around flexibility for candidates that form crystalline drug or phase-separate without an amorphous dispersion structure.
What polymer properties and polymer families are claimed?
Direct answer: The formulation must use a hydrophilic polymer; the later dependent claims specify a minimum Tg (≥50°C) and cover N-vinylpyrrolidone polymers, including copovidone.
Claim 3: polymer thermal constraint
Claim 3: polymer has Tg ≥ 50°C.
Interpretation for coverage: Any hydrophilic polymer meeting that Tg threshold could fall within Claim 3 if used alongside the other limitations (active amorphous + required surfactant).
Claim 7: N-vinyl pyrrolidone family
Claim 7: polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.
Claim 8: copovidone
Claim 8: polymer is copovidone.
Claim 8–12 and 9–11: how the polymer narrows with surfactants
Once copovidone is selected, dependents specify particular surfactants and solid dispersion character:
- Claim 9: surfactant = d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)
- Claim 10: surfactant = sorbitan mono laurate
- Claim 11: solid dispersion is an amorphous solid dispersion
- Claim 12: solid dispersion is a solid solution comprising surfactant
Claim 12 impact: If the product is engineered to behave as a solid solution rather than a dispersion, Claim 12 adds an extra infringement hook, so design strategies that claim “solid solution” instead of dispersion may still be captured.
What surfactant coverage exists: HLB rules and specific named surfactants?
Direct answer: The patent requires a surfactant in Claim 1 and adds emulsifier-character constraints by HLB in dependent claims; it also includes specific surfactant embodiments (TPGS and sorbitan mono laurate).
Claim 4 and HLB ≥ 10
Claim 4: surfactant has HLB ≥ 10.
This sets a measurable parameter for many nonionic surfactants and PEGylated amphiphiles.
Claim 5 and “below 10” co-surfactant
Claim 5: further comprising another surfactant with HLB < 10.
This gives explicit coverage for systems using a primary high-HLB solubilizer/emulsifier plus a lower-HLB component (often used for interfacial tuning).
Claim 18–20: “at least two surfactants” with opposing HLB bands
- Claim 18: at least two surfactants, one HLB ≥ 10, the other HLB < 10
- Claim 19: same concept as Claim 18 but in the context of Claim 6 (amorphous solid dispersion)
- Claim 20: same concept as Claim 18 but in the context of Claim 11 (amorphous solid dispersion)
- Claim 21: same concept as Claim 18 but in the context of Claim 12 (solid solution)
Practical coverage consequence: If a product uses multiple surfactants with a split high/low HLB design, it is pulled directly into multiple claim families.
What active ingredient specificity means for freedom-to-operate
Direct answer: The active is defined with extreme structural and stereochemical specificity. That typically makes the claim scope narrow to formulations using that exact compound (or a claimed pharmaceutically acceptable salt).
Active ingredient definition in the claims
Claim 1 enumerates:
- dimethyl
- (2S,2′S) stereochemical descriptors
- a bis(azanediyl) and bis(oxomethylene) scaffold with bis(pyrrolidine-2,1-diyl)
- an appended 4-tert-butylphenyl moiety on a pyrrolidine ring
- a dicarbamate motif with bis(3-methyl-1-oxobutane-2,1-diyl) fragments
FTO read: Any competitor formulation using a different prodrug, different stereoisomeric blend, or a different active entity would not satisfy the active limitation, even if the amorphous polymer/surfactant system matches.
Do the claims cover combination regimens with other HCV antivirals?
Direct answer: Yes. Claims 13–17 are composition claims that include the defined amorphous solid active plus added anti-HCV agents, including specified protease inhibitors, polymerase inhibitors, telaprevir/boceprevir, and enumerated DAAs.
Claim 13: “another anti-HCV agent”
Claim 13: further comprises another anti-HCV agent.
Claim 14: HCV protease inhibitor
Claim 14: further comprises an HCV protease inhibitor.
Claim 15: HCV polymerase inhibitor
Claim 15: further comprises an HCV polymerase inhibitor.
Claim 16: telaprevir or boceprevir
Claim 16: further comprises telaprevir or boceprevir.
Claim 17: selected-agent list of DAAs
Claim 17 enumerates a group including (as provided):
- ITMN-191, BI-201335, VBY-376, VX-500, PHX-B, ACH-1625, IDX136, IDX316, VX-813, SCH 900518, TMC-435, MK-7009, IDX-PI, R7128, MK-3281, PF-868554, PF-4878691, IDX-184, IDX-375, PPI-461, BILB-1941, GS-9190, BMS-790052, ABT-333, ABT-072
Coverage consequence: The claims are broad across HCV DAA classes at the combination level, but anchored to the same defined amorphous solid active. This is relevant for combination therapy products, co-packaged therapies, or fixed-dose combinations if they can be characterized as a single solid composition meeting the amorphous polymer/surfactant limitations.
What “claim pathways” exist for infringement analysis?
Direct answer: US 8,686,026 presents at least four main infringement pathways depending on product characterization and excipient selection.
Pathway A: minimal requirements under Claim 1
- active matches the stereochemical dicarbamate definition
- drug present in amorphous form
- includes hydrophilic polymer
- includes surfactant
Pathway B: solid dispersion pathway (Claim 2 and dependents)
- meets Claim 1
- plus formulation is a solid dispersion including active, polymer, surfactant
Pathway C: polymer Tg and N-vinyl pyrrolidone family (Claims 3, 7, 8)
- meets Claim 2
- polymer has Tg ≥ 50°C
- polymer is N-vinylpyrrolidone homopolymer or copolymer
- specific coverage if polymer is copovidone
Pathway D: surfactant selection with HLB thresholds and named examples (Claims 4–6, 9–12, 18–21)
- meets Claim 3
- surfactant HLB ≥ 10
- optional second surfactant HLB < 10
- specific embodiments:
- copovidone + TPGS
- copovidone + sorbitan mono laurate
- characterization as amorphous solid dispersion or as solid solution
How strong is the patent’s formulation estate logic from the claim architecture?
Direct answer: The claim set stacks multiple measurable constraints (amorphous form, Tg, HLB) while also retaining an anchor-independent claim (Claim 1) that only requires amorphous solid + polymer + surfactant.
Strength factors
- Amorphous form is a discrete, testable state tied to solid-state properties.
- Tg ≥ 50°C and HLB thresholds create objective boundaries that can be analyzed using DSC/DMTA and surfactant spec sheets or calculation methods.
- Specific polymer identity (copovidone) plus specific surfactants provide hard-to-evade embodiments.
- Solid dispersion and solid solution coverage reduces “semantic” design-around risk.
Potentially weaker aspects (in the claim text)
- Claim 1 uses broad functional language for “hydrophilic polymer” and “pharmaceutically acceptable surfactant,” which can increase debate over whether a specific excipient qualifies, even though dependents narrow materially.
- The claims’ active definition is so specific that product changes to active identity (prodrug/stereoisomer/salt) can avoid the claim regardless of excipient system.
What claim gaps and design-around options appear within the written claims?
Direct answer: Based on the claim limitations you provided, design-around themes cluster around: (i) changing active identity, (ii) ensuring non-amorphous or non-dispersion state, and/or (iii) excipient selection that avoids meeting specific Tg or HLB constraints (particularly for dependents).
Active identity
Avoid literal scope by using:
- a different stereochemical isomeric composition,
- a different prodrug or salt not captured by the “dimethyl (2S,2′S) … dicarbamate” definition,
- a substantially different active chemical entity.
Amorphous state / dispersion character
Try to avoid:
- “amorphous form” (produce crystalline or stable non-amorphous microstructure),
- “solid dispersion” characterization (though Claim 1 still requires amorphous form + polymer + surfactant).
Polymer and surfactant constraints at the dependent level
For dependents:
- avoid Tg ≥ 50°C polymers if the infringement theory targets Claim 3 dependents;
- avoid HLB ≥ 10 for the primary surfactant and avoid the two-surfactant HLB split for Claims 18–21;
- avoid copovidone and the named surfactants if those dependents are asserted.
Key point: Even if dependents are avoided, Claim 1 remains a broad backstop, so successful design-around typically requires simultaneous changes to multiple elements.
What does the patent likely cover commercially: product form and patient use?
Direct answer: The claims cover an oral or systemically administered solid formulation style typical for HCV DAA combination regimens, where amorphous solid dispersions are used to improve solubility/bioavailability of an active that is poorly soluble in crystalline form. The presence of polymer + surfactant + amorphous state points to a formulation intended to manage dissolution and exposure.
Combination claims imply coverage for combination regimens with DAAs, but whether the invention is used in a fixed-dose unit vs co-administration depends on how “composition” is manufactured and presented.
Orange Book and FDA status: what can be concluded from the claim text alone?
Direct answer: None. Your prompt provides no Orange Book listings, application numbers, listed patent numbers, FDA approval dates, or NDA/ANDA/BLA mapping to US 8,686,026. Without those, it is not possible to state regulatory listing status, exclusivity periods, or Paragraph IV linkage.
Litigation, licensing, and expiry: what can be concluded from the claim text alone?
Direct answer: None. Your prompt provides only claim text and no docket numbers, settlement terms, judicial decisions, prosecution history, or maintenance/adjustment status needed to compute expiration or to map legal events to specific asserted patents.
Key takeaway: what the claim set most effectively protects
- A specific stereochemical active (dimethyl dicarbamate) as an amorphous solid.
- Formulated with required hydrophilic polymer + surfactant.
- Additional constraints that materially strengthen enforceability: polymer Tg ≥ 50°C, N-vinylpyrrolidone/copolymer (copovidone), surfactant HLB ≥ 10, and optional low-HLB co-surfactant.
- Explicit coverage of TPGS and sorbitan mono laurate in copovidone systems.
- Ability to capture combination HCV regimens by adding protease/polymerase inhibitors and specific listed DAAs.
Key Takeaways
- Claim 1 is the broadest anchor: amorphous solid active + hydrophilic polymer + surfactant.
- Claim 2/6 expand protection to solid dispersion/amorphous solid dispersion, and Claim 12 extends to solid solution characterization.
- The enforceability profile strengthens in dependents via Tg ≥ 50°C, N-vinylpyrrolidone polymers, and copovidone.
- Surfactant scope is constrained through HLB ≥ 10 and includes explicit named examples TPGS and sorbitan mono laurate, plus multi-surfactant HLB band combinations.
- Combination coverage exists via added HCV DAAs, including explicit telaprevir and boceprevir and an enumerated DAA list.
FAQs
1) Does US 8,686,026 require a specific drug-to-polymer ratio?
No ratio is provided in the claim text you supplied; the limitations are structural (active identity) and materials characterization (amorphous/solid dispersion) and property thresholds (Tg, HLB) in dependent claims.
2) Can a product avoid the patent by using a non-amorphous form?
Avoiding “amorphous form” would be a direct route to non-infringement of Claim 1, since amorphous state is a required element.
3) Is copovidone mandatory to infringe?
No. Copovidone is required only for dependent claims (notably Claim 8) that narrow polymer identity. Claim 1 only requires a hydrophilic polymer.
4) Are HLB values only relevant to dependent claims?
The HLB limits appear in dependents (e.g., Claims 4–5 and 18–21). Claim 1 requires a surfactant but does not impose an HLB threshold in your provided text.
5) Do the claims cover solid solutions instead of solid dispersions?
Yes. Claim 12 explicitly covers a “solid solution” comprising the surfactant within the copovidone/solid dispersion framework.
References
- United States Patent US 8,686,026. (Claims provided in the prompt).
